| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 34 | 39.0x | 17.3x | Bottom tier | |
Growth | 45 | 10.0% | 7.1% | Around median | |
Quality | 70 | 7.7% | 4.5% | Top tier | |
Safety | 70 | — | 2.6x | Top tier | |
Capital Return | 90 | 2.29% | 0.06% | Top tier | |
Momentum | 55 | -21.0% | -1.6% | Around median | |
Sentiment | 71 | 15 | 3 | Top tier |
The floor: what the company is worth if growth stopped today
68% of today's price is what a buyer pays for growth that has not happened yet.
10-year US Treasury yield 4.96% as of 2026-10-22. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Abbott Laboratories, listed under ticker ABT on the NYSE, operates across medical devices, diagnostics, nutrition, and established pharmaceuticals in emerging markets. The company generates revenue from sales of devices and sensors, including Libre diabetes monitoring products, laboratory instruments, reagents, and tests, as well as nutrition products such as Ensure and pharmaceuticals. This diversification links its business to chronic disease management, cardiac procedures, and recurring testing, while the addition of Exact Sciences expanded its presence in cancer diagnostics through Cologuard and Cologuard Plus.
In quarter 2 of fiscal year 2026 ended 2026-06-30, revenue according to EL7 data was approximately $12.6 billion, net income was $928.0 million, and diluted earnings per share were $0.53. The gross margin was 58.0%, and the operating margin as calculated by EL7 was approximately 14.2% for the same period, while operating cash flow according to EL7 data was approximately $2.5 billion. A reliable comparison of annual revenue growth and annual margin changes is unavailable because the revenue line item is defined differently between the two periods.
Business performance in quarter 2 of fiscal year 2026 ended 2026-06-30 shows variation among the portfolio's growth drivers; continuous glucose monitoring sales exceeded $2 billion, growing 9.5% compared with the same quarter of the previous year under the company's comparable sales definition. Established pharmaceuticals grew 9%, cardiac rhythm management 9.5%, and heart failure devices 9% on the same basis, while rapid and molecular diagnostics declined 8% because of a weak respiratory testing season. Abbott's ability to accelerate growth therefore depends on the performance of Libre, cardiac devices, and cancer diagnostics, alongside nutrition regaining momentum.
Q2 FY2026
Last 12 months to 2026-06-30
When: 2026-10-21
Adjusted earnings per share for quarter 3 of fiscal year 2026 versus the $1.38–1.46 range in the expected earnings announcement
Comparable sales growth guidance for fiscal year 2026 versus the 6.5%–7.5% range in the expected earnings announcement
The median target of 9 analysts in the 2026-10-19 snapshot was approximately $120, within a $92–134 range, an estimate that incorporates growth expectations and is inherently tilted toward optimism. The value based on the industry multiple is $116, within a $90–202 range, based on next year's earnings and a median multiple of 19.5 times across 45 companies; it measures Abbott's value if priced like its peers. The no-growth value is $20 at a discount rate of 8.7%, measuring the value remaining if current after-tax operating profit stays constant forever. The analyst estimate is close to the industry-multiple value, while the low no-growth value illustrates the first two estimates' dependence on continued earnings growth rather than maintaining the current level.
Figures in the text are as of 2026-10-20; the live price is shown at the top of the page.
Continuous glucose monitoring sales exceeded $2 billion in quarter 2 of fiscal year 2026 ended 2026-06-30, growing 9.5% compared with the same quarter of the previous year. In the same period, cardiac rhythm management grew 9.5% and heart failure devices grew 9% on the same basis, supported by Avera and the broader adoption of cardiac devices. The 2026-07-16 call added that Bolt and Tactiflex Duo support acceleration in cardiac electrophysiology, giving the company more than one growth path within medical devices.
The 2026-09-30 news report reported the launch of SimpleScreen CRC, approved by the Food and Drug Administration and covered by Medicare for adults aged 45 and older. This expands the options for reaching patients who avoid colonoscopy and conventional screening. However, management explained on the 2026-07-16 call that blood tests do not have the same sensitivity as Cologuard for detecting precancerous polyps and early stages, and therefore presents them as an additional entry point to screening alongside stool tests.
Automated analysis for informational purposes only — not investment advice.
Continuous glucose monitoring sales growth compared with the 9.5% threshold in the expected earnings announcement
Diluted earnings per share were $0.53 in quarter 2 of fiscal year 2026 ended 2026-06-30, with net income of $928.0 million. The $5.45–5.60 range announced by management on the 2026-07-16 call is guidance for adjusted earnings per share for the full fiscal year 2026. The two figures differ in period and accounting basis, and the company explained that it did not provide a forward-looking equivalent under generally accepted accounting principles for the adjusted guidance because of the difficulty of predicting the timing and impact of certain items.
Operating cash flow according to EL7 data was approximately $9.9 billion for the trailing 12 months through 2026-06-30, equivalent to 183% of net income of $5.4 billion for the same period. Free cash flow as calculated by EL7 (operating cash flow minus capital expenditures) for the trailing 12 months through 2026-06-30 was approximately $7.9 billion. In comparison, debt according to EL7 data was approximately $32.6 billion and cash and short-term investments were $5.1 billion at the end of quarter 2 of fiscal year 2026 ended 2026-06-30, making cash generation a strength while the debt level remains important, without these figures alone being sufficient to assess its maturity schedule.
Management set an adjusted earnings per share range for quarter 3 of fiscal year 2026 of $1.38–1.46 on the 2026-07-16 call. Maintaining comparable sales growth guidance for fiscal year 2026 at 6.5%–7.5% compared with the previous fiscal year will test progress in nutrition, core laboratories, cardiac electrophysiology, and cancer diagnostics. Comparing continuous glucose monitoring growth with the 9.5% level recorded compared with the same quarter of the previous year in quarter 2 of fiscal year 2026 ended 2026-06-30 will also clarify the extent of acceleration in this business.